Vaglini M, Belli F, Marolda R, Prada A, Santinami M, Cascinelli N
Eur J Surg Oncol. 1987 Apr;13(2):127-9.
The aim of this paper is to evaluate the effectiveness of DTIC when employed at a local level in hyperthermic antiblastic perfusion (HAP) for stage IIIA-IIIAB melanoma patients. Twenty-seven consecutive patients have been treated at the National Cancer Institute of Milan from October 1983 to June 1985. All the patients were submitted to HAP at 40 degrees for 60' with DTIC at the dosage of 2.5 g/m2 [corrected] for lower extremities and 1.5 g/m2 [corrected] for upper extremities. We observed a complete local response in three patients and a partial local response 50% in seven patients, 10 patients has a response less than 50% and 4 patients did not show any response. After surgical removal of the residual tumor when possible, 14 patients are alive without detectable disease while 11 are alive with disease and two dead for progression. No serious complications were observed. These data indicate that DTIC seems able to obtain in HAP, results superimposable to L-PAM without any significant toxicity.
本文旨在评估达卡巴嗪（DTIC）在局部高温抗瘤灌注（HAP）中用于ⅢA - ⅢAB期黑色素瘤患者时的有效性。1983年10月至1985年6月期间，米兰国家癌症研究所连续治疗了27例患者。所有患者均在40摄氏度下接受HAP治疗60分钟，下肢使用达卡巴嗪的剂量为2.5 g/m²[校正后]，上肢为1.5 g/m²[校正后]。我们观察到3例患者出现完全局部缓解，7例患者出现50%的部分局部缓解，10例患者的缓解率低于50%，4例患者未显示任何缓解。在可能的情况下手术切除残留肿瘤后，14例患者存活且无疾病可检测，11例患者存活但有疾病，2例患者因疾病进展死亡。未观察到严重并发症。这些数据表明，达卡巴嗪在HAP中似乎能够获得与左旋苯丙氨酸氮芥（L - PAM）相当的结果，且无任何明显毒性。
